Sernova announced clinical data supporting the potential of its Cell Pouch system as a “functional cure” for insulin-dependent diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch system as an implantable and scalable medical device that forms a natural environment in the body for long-term survival and function of therapeutic cells that release necessary proteins or […]
Diabetes
Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line. Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest. In the […]
Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology
Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology. Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Get the full story […]
One Drop studies show improved attitudes toward CGM, diabetes management platform
One Drop announced positive data from multiple studies evaluating the opinions of people with diabetes on continuous glucose monitoring. New York-based One Drop presented new research about attitudes and adoption of continuous glucose monitors (CGMs) among people with type 2 diabetes at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Get the full […]
Virta Health reports positive results from diabetes reversal study
Virta Health announced today that its diabetes reversal treatment demonstrated improvements in those with type 2 diabetes. San Francisco-based Virta Health launched in 2017 with the goal of reversing Type 2 diabetes using its technology platform to enable personalized remote care. Virta’s offerings include physician supervision, health coaches, an app and biomarker tracking tools, as well as […]
Bigfoot Biomedical’s Bigfoot Unity demonstrates strong glycemic control in Type 2 diabetes
Bigfoot Biomedical announced data supporting the use of its Bigfoot Unity system for improving glycemic control in those with diabetes. Data from a real-world retrospective analysis suggests that, for those on multiple daily injections (MDI) of insulin, Bigfoot Unity has the potential to provide rapid and durable glycemic control improvements. Milpitas, California–based Bigfoot presented the real-world […]
Late-breaking data supports Abbott FreeStyle Libre 3 in 14-day glucose monitoring
Abbott (NYSE:ABT) announced data demonstrating the accuracy of its next-generation FreeStyle Libre 3 continuous glucose monitor (CGM). The latest version of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world at the size of just two stacked U.S. pennies — picked up FDA clearance for people with diabetes aged […]
Insulet’s Omnipod 5 “significantly improves” glycemic outcomes in very young children
Insulet (Nasdaq:PODD) announced data supporting the use of its Omnipod 5 automated insulin delivery system in young children. Acton, Massachusetts–based Insulet’s Omnipod 5 significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use, according to the company. Earlier this year, the […]
Real-world data backs Medtronic’s next-gen MiniMed 780G insulin pump
Medtronic (NYSE:MDT) announced positive real-world data supporting its next-generation MiniMed 780G insulin pump system. Results from real-world analyses in Europe and Chile, along with clinical data, were presented by Medtronic at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. According to a news release, the MiniMed 780G advanced hybrid closed loop system, designed with […]
Abbott to develop biowearable for continuous monitoring of glucose, ketone levels
Abbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels. The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter. Get the full story at our sister site, Drug Delivery Business News.
Study backs DarioHealth’s digital therapeutics for managing diabetes
DarioHealth (Nasdaq:DRIO) announced today that multiple research studies support its digital therapeutics for diabetes management. New York-based DarioHealth presented the data from the new studies at the American Diabetes Association’s (ADA) 82nd Scientific Sessions in New Orleans. Two of the studies add to DarioHealth’s evidence supporting an integrated approach to managing multiple chronic conditions, while the third […]
